Saphnelo (anifrolumab-fnia)

Saphnelo (anifrolumab-fnia) is a type I interferon (IFN) receptor antagonist used to treat adults with moderate to severe systemic lupus erythematosus (SLE), who are taking other lupus drugs, regardless of race or ethnicity standard therapy.

Recommended Dosage: Saphnelo is supplied as a single-dose vial. It must be diluted before intravenous administration. The recommended dosage regimen of Saphnelo injection is 300 mg, administered as an intravenous infusion over a 30-minute time span, every 4 weeks.

If a planned/scheduled infusion of Saphnelo is missed, administer it as promptly as possible. A minimum interval of 14 days between infusions should be maintained.

• Severe and sometimes fatal infections have occurred in those with immunosuppressive agents, including Saphnelo injection. If a patient develops an infection or is not responding to standard anti-infective therapy, assess the patient precisely and interrupt treatment until the infection resolves.
• Events of angioedema, infusion-related reactions, and serious hypersensitivity reactions have been noticed following Saphnelo administration. Consider pre-medication prior to infusion for those with a known history of these reactions. If infusion-related reactions, or hypersensitivity reactions, promptly interrupt the infusion.
• The use of immunosuppressants may increase the risk of malignancies. Consider the benefit-risk in those with known risk factors for the development of reoccurrence of malignancy before using Saphnelo. In those who develop malignancies, consider the risk-benefit of continued therapy with Saphnelo.
• Saphnelo 300 mg/2 mL medication has not been evaluated in combination with other biologic therapies, including B-cell-targeted therapies. Therefore, the administration of this injection is not recommended for use along with biological therapies.
• Update immunizations, as per the current immunization guidelines, before initiating treatment with Saphnelo. Concurrent use of live or live-attenuated vaccines should be avoided in patients treated with this medicinal product.

What documents are required to import SAPHNELO to India?

SAPHNELO (anifrolumab-fnia) injections can be imported by patients or government hospitals on the name of the patients only. 

The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patients Identity Proof (issued by the government of India)

How does the order be confirmed?

The order will be confirmed only after the receipt of:

• A valid prescription from Doctor
• Import permit if applicable

Is SAPHNELO available in India?

SAPHNELO (anifrolumab-fnia injection) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator providing input

• On availability of Saphnelo in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune etc.)
• Medicine Price.
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
• Ensuring 100% transparency.

SAPHNELO can be made available to patients, doctors, and hospitals in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.

IPN (Indian Pharma Network) can facilitate the supply of SAPHNELO (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable).

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Saphnelo Injection price in India. 

We take to guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

What is the Generic Name for the trade name drug Saphnelo®?

Anifrolumab-fnia is a Generic Name for the trade name drug Saphnelo®.

What is the Manufacturer’s Name of Saphnelo®?

Saphnelo® is manufactured by AstraZeneca.

Where can I get Saphnelo injections at the best price in India?

To get the best Saphnelo price in India, kindly contact Indian Pharma Network (a WHO GDP & ISO 9001 : 2008 certified company). For Saphnelo®, a valid medical prescription is required from your treating physician. 

Is Saphnelo® approved by the FDA?

Yes, Saphnelo® is approved by the FDA. Date of first/initial approval: July 30, 2021.

What are the most common side effects of Saphnelo®? 

The most common saphnelo side effects are upper respiratory tract infections, nasopharyngitis, infusion related reactions, bronchitis, herpes zoster and cough. 

What is the dosage and form of Saphnelo® supplied?

Saphnelo® is supplied as an Injection: 300 mg/2 mL (150 mg/mL) in a single-dose vial for intravenous use or administration. 

How much does Saphnelo® cost in India?

The saphnelo cost in India is less and can vary. In order to procure this SLE medication authentically, you can Call or WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

What are the storage conditions of Saphnelo®?

Saphnelo comes in a carton containing one single dose vial. Store this medicine in a refrigerator at 36 to 46°F (2 to 8°C) in the original carton in order to protect it from light. Neither freeze nor shake it.

Is it safe to buy Saphnelo injections online from India?

Yes, you can buy Saphnelo injection online at the best price from the Indian Pharma Network (IPN) if the medicine Saphnelo has not been approved or is not available in your home country.

What are the Highlights of prescribing information for Saphnelo®?

Click Here to download full  Saphnelo prescribing information.